|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Doroshow DB, Sanmamed MF, Hastings K,
Politi K, Rimm DL, Chen L, Melero I, Schalper KA and Herbst RS:
Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin
Cancer Res. 25:4592–4602. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Memmott RM, Wolfe AR, Carbone DP and
Williams TM: Predictors of response, progression-free survival, and
overall survival in patients with lung cancer treated with immune
checkpoint inhibitors. J Thorac Oncol. 16:1086–1098. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Garon EB, Kim DW, Cho BC,
Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I,
et al: Five year survival update from KEYNOTE-010: Pembrolizumab
versus docetaxel for previously treated, programmed death-ligand
1-positive advanced NSCLC. J Thorac Oncol. 16:1718–1732. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brueckl WM, Ficker JH and Zeitler G:
Clinically relevant prognostic and predictive markers for
immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung
cancer (NSCLC). BMC Cancer. 20:11852020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huai Q, Luo C, Song P, Bie F, Bai G, Li Y,
Liu Y, Chen X, Zhou B, Sun X, et al: Peripheral blood inflammatory
biomarkers dynamics reflect treatment response and predict
prognosis in non-small cell lung cancer patients with neoadjuvant
immunotherapy. Cancer Sci. 114:4484–4498. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lei W, Wang W, Qin S and Yao W: Predictive
value of inflammation and nutritional index in immunotherapy for
stage IV non-small cell lung cancer and model construction. Sci
Rep. 14:175112024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yildirim S, Dogan A, Akdag G, Yasar ZY,
Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, et
al: The role of laboratory indices on treatment response and
survival in breast cancer receiving neoadjuvant chemotherapy. Sci
Rep. 14:121232024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fucà G, Guarini V, Antoniotti C, Morano F,
Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L,
Sartore-Bianchi A, et al: The pan-immune-inflammation value is a
new prognostic biomarker in metastatic colorectal cancer: Results
from a pooled-analysis of the Valentino and TRIBE first-line
trials. Br J Cancer. 123:403–409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sahin AB, Cubukcu E, Ocak B, Deligonul A,
Oyucu Orhan S, Tolunay S, Gokgoz MS, Cetintas S, Yarbas G, Senol K,
et al: Low pan-immune-inflammation-value predicts better
chemotherapy response and survival in breast cancer patients
treated with neoadjuvant chemotherapy. Sci Rep. 11:146622021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Topkan E, Selek U, Kucuk A and Pehlivan B:
Low pre-chemoradiotherapy pan-immune-inflammation value (PIV)
measures predict better survival outcomes in locally advanced
pancreatic adenocarcinomas. J Inflamm Res. 15:5413–5423. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao W, Li J, Feng W, Kong W, Shen Y, Chen
Z and Yang H: Pan-immune-inflammation value: A new prognostic index
in epithelial ovarian cancer. BMC Cancer. 24:10522024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duan L, Guo W, Yin S, Yang S, Liu J, Duan
Y, Dong G, Li W and Chen F: The baseline pan-immune-inflammation
value (PIV) and PILE in predicting clinical outcomes and
therapeutic response for primary central nervous system lymphoma. J
Inflamm Res. 17:5347–5363. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Predictive value of neutrophil/lymphocyte ratio for efficacy of
preoperative chemotherapy in triple-negative breast cancer. Ann
Surg Oncol. 23:1104–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Borghaei H, Gettinger S, Vokes EE, Chow
LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O,
Frontera OA, Chiari R, et al: Five-year outcomes from the
randomized, phase III trials checkmate 017 and 057: Nivolumab
versus docetaxel in previously treated non-small-cell lung cancer.
J Clin Oncol. 39:723–733. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ismail RK, Schramel F, van Dartel M,
Pasmooij AMG, Cramer-van der Welle CM, Hilarius DL, de Boer A,
Wouters MWJM and van de Garde EMW: Individual patient data to allow
a more elaborated comparison of trial results with real-world
outcomes from first-line immunotherapy in NSCLC. BMC Med Res
Methodol. 23:12023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cramer-van der Welle CM, Verschueren MV,
Tonn M, Peters BJM, Schramel F, Klungel OH, Groen HJM and van de
Garde EMW; Santeon NSCLC Study Group, : Real-world outcomes versus
clinical trial results of immunotherapy in stage IV non-small cell
lung cancer (NSCLC) in the Netherlands. Sci Rep. 11:63062021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Linardou H, Lampaki S, Koliou GA, Vozikis
A, Boutis A, Nikolaidi A, Kontogiorgos I, Papakotoulas P,
Christopoulou A, Spyratos D, et al: Real-world data and economic
evaluation of nivolumab in previously treated non-small cell lung
cancer greek patients. Anticancer Res. 43:2799–2812. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Geiger-Gritsch S, Olschewski H, Kocher F,
Wurm R, Absenger G, Flicker M, Hermann A, Heininger P, Fiegl M,
Zechmeister M, et al: Real-world experience with anti-PD-1/PD-L1
monotherapy in patients with non-small cell lung cancer: A
retrospective Austrian multicenter study. Wien Klin Wochenschr.
133:1122–1130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dudnik E, Moskovitz M, Daher S, Shamai S,
Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O,
et al: Effectiveness and safety of nivolumab in advanced non-small
cell lung cancer: The real-life data. Lung Cancer. 126:217–223.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luján M, Lema M, Preciado B, Lema C,
Egurrola J, Cardona A, González D, Mantilla W, Pino L, Rojas G, et
al: Real-world evidence of nivolumab for non-small-cell lung cancer
in a developing country. J Investig Med. 71:502–510. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vokes EE, Ready N, Felip E, Horn L, Burgio
MA, Antonia SJ, Frontera OA, Gettinger S, Holgado E, Spigel D, et
al: Nivolumab versus docetaxel in previously treated advanced
non-small-cell lung cancer (CheckMate 017 and CheckMate 057):
3-year update and outcomes in patients with liver metastases. Ann
Oncol. 29:959–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Gong L, Gu P, Hua Y, Sun Y, Ni S,
Zhou X and Tang Z: Pan-immune-inflammation and its dynamics:
Predictors of survival and immune-related adverse events in
patients with advanced NSCLC receiving immunotherapy. BMC Cancer.
23:9442023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Q, Zhong W, Xiao Y, Lin G, Lu J, Xu
L, Zhang G, Liu A, Du J and Wu B: Pan-immune-inflammation value
predicts immunotherapy response and reflects local antitumor immune
response in rectal cancer. Cancer Sci. 116:350–366. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Certa F, Horn PA, Keyl J, Mende B, Lueong
S, Hilser T, Theurer S, Virchow I, Zaun Y, Pogorzelski M, et al:
ABO-blood group associates with survival outcomes in patients with
metastatic non-small cell lung cancer treated with pembrolizumab
monotherapy. Thorac Cancer. 16:e700372025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen R, Hakimi K, Zhang X, Messer K and
Patel SP: Patient blood type is associated with response to immune
checkpoint blockade in metastatic cancer. Oncologist. 27:e739–e747.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boku S, Ikoma T, Yasuda T, Shibata N,
Sakagami T, Suzuki K, Fujisawa T, Iwai H and Kanai M: Relationship
between the effectiveness of pembrolizumab monotherapy and ABO
blood type in recurrent and metastatic squamous cell carcinoma of
the head and neck. Discov Oncol. 16:13022025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Deng C, Zhang N, Wang Y, Jiang S and Lu M:
High systemic immune-inflammation index predicts poor prognosis in
advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Medicine (Baltimore). 98:e168752019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun W, Wen CP, Lin JK, Wen CL, Pu X, Huang
M, Tsai MK, Tsao CK, Wu X and Chow WH: ABO blood types and cancer
risk: A cohort study of 339,432 subjects in Taiwan. PLoS One.
11:e01566122016.PubMed/NCBI
|
|
33
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung ımmune
prognostic ındex with ımmune checkpoint ınhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
